InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-02-13 | Angus S King, Jr. | senate | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B+44.7% | $45.04B+32.0% | $34.12B | — | — |
| Cost of sales | $11.05B+31.3% | $8.42B+18.9% | $7.08B+6.8% | $6.63B-9.3% | $7.31B |
| Research and development | $13.34B+21.3% | $10.99B+18.0% | $9.31B+29.5% | $7.19B+3.8% | $6.93B |
| Marketing, selling, and administrative | $11.09B+29.1% | $8.59B+16.1% | $7.40B+15.0% | $6.44B+0.1% | $6.43B |
| Acquired in-process research and development | $2.91B-11.3% | $3.28B-13.7% | $3.80B+318.3% | $908.5M | — |
| Asset impairment, restructuring, and other special charges | $484.0M-43.8% | $861.0M+1166.2% | $68.0M | — | — |
| Other—net, (income) expense | $571.0M+160.7% | $219.0M+325.8% | -$97.0M | — | — |
| Costs, expenses, and other | $39.45B+21.9% | $32.36B+17.4% | $27.57B+26.8% | $21.73B-1.9% | $22.16B |
| Income before income taxes | $25.73B+102.9% | $12.68B+93.5% | $6.55B-3.7% | $6.81B+10.6% | $6.16B |
| Income taxes | $5.09B+143.6% | $2.09B+59.1% | $1.31B | — | — |
| Net income | $20.64B+94.9% | $10.59B+102.1% | $5.24B-16.1% | $6.24B+11.9% | $5.58B |
| Basic (in dollars per share) | $23.0M+95.6% | $11.8M+102.1% | $5.8M-16.0% | $6.9M+12.7% | $6.2M |
| Diluted (in dollars per share) | $22.9M+96.0% | $11.7M+101.9% | $5.8M-15.9% | $6.9M+12.7% | $6.1M |
| Basic (in shares) | $897.3M-0.4% | $900.6M+0.0% | $900.2M-99.9% | $901.74B-0.6% | $906.96B |
| Diluted (in shares) | $899.3M-0.5% | $904.1M+0.1% | $903.3M-99.9% | $904.62B-0.8% | $911.68B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
Jim Cramer Believes “Novo Nordisk Is Going to Lose a Lot of Share on the Pill to Eli Lilly”
3 things to look out for on Thursday
Eli Lilly (LLY) Q1 Earnings: What To Expect